Zuklopentyksol | Clopixol-Akufaz solution in oil 50 mg / ml 1 ml 5 pcs.

Release form

Injection

Packing

5 ampoules of 1 ml.

Pharmacological action

Clopixol-acufase has a neuroleptic, antipsychotic, sedative effect.

Blocks dopamine receptors in the brain.

Contraindications

Acute poisoning with alcohol, barbiturates, opiates, coma.

Use during pregnancy and lactation

Contraindicated. Nursing mothers should stop breastfeeding.

Special instructions

Malignant antipsychotic syndrome (CNS) is rare, but a possible fatal complication when using antipsychotics. The main characteristics of ZNS are hyperthermia, muscle stiffness and impaired consciousness in combination with autonomic nervous system dysfunction (labile blood pressure, tachycardia, increased sweating). In addition to the immediate cessation of antipsychotic administration, the use of general supportive measures and symptomatic treatment is imperative.

Composition of

1 ml injection contains:

zuclopentixol acetate (in Viscoleo vegetable oil) 50 mg.

Dosage and Administration

Clopixol-acuphase is prescribed as a deep intramuscular injection into the upper outer quadrant of the gluteal region. Local tolerance is good. Dosage is selected individually depending on the condition of the patient.

Recommended intramuscular injection volume is 1-3 ml (50-150 mg). If necessary, repeated injections are carried out with an interval of 2-3 days. For some patients, an additional injection may be given 24-48 hours after the first injection.

When switching to oral treatment with clopixol 2-3 days after the final injection of clopixol-acufas (100 mg injections), the patient should be given an oral dose of 40 mg, if possible in several doses.

If necessary, the dose may be increased by 10-20 mg every 2-3 days to 75 mg / day or more.

Side effects

Extrapyramidal disorders, tardive dyskinesia, malignant antipsychotic syndrome, drowsiness are possible dizziness, dry mouth, accommodation disturbance, urinary retention, constipation, tachycardia, orthostatic hypotension, changes in liver tests.

Drug interaction

Enhances the sedative effect of alcohol, barbiturates and other drugs that depress the central nervous system, reduces - levodopa and other adrenergic drugs.

Reduces the hypotensive effect of guanethidine and its analogues.

Metoclopramide and piperazine increase the risk of extrapyramidal disorders.

Overdose

Symptoms: drowsiness, hypo- or hyperthermia, hypotension, extrapyramidal symptoms, convulsions, shock, coma.

Treatment: symptomatic and supportive.

Steps must be taken to support the activities of the respiratory and cardiovascular systems.

Do not use epinephrine (epinephrine) because this can lead to a subsequent decrease in blood pressure.

Convulsions can be stopped with diazepam and extrapyramidal symptoms with biperiden.

Storage Conditions

At a temperature not exceeding 25 РC.

Dosage form

solution for injection

H. Lundbeck A / O, Denmark